Molecular mechanisms of peritoneal permeability - Research growth factors

Peritoneal Dialysis International

Volumn 21, Issue SUPPL. 3, 2001, Pages

  Devuyst, Olivier ^a  

^a UCL   (Belgium)

Author keywords

Advanced glycation; Basic fibroblast growth factor; Neoangiogenesis; Nitric oxide; Nitric oxide synthase; Peritoneal membrane; Ultrafiltration; Vascular endothelial growth factor

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CARBONYL DERIVATIVE; GLUCOSE; GLYOXAL; GROWTH FACTOR; ICODEXTRIN; METHYLGLYOXAL; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BLOOD VESSEL; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CAPILLARY; CONNECTIVE TISSUE; DEATH; ENZYME ACTIVITY; FIBROSIS; GLUCOSE ABSORPTION; HISTOPATHOLOGY; HUMAN; INTERSTITIUM; KIDNEY FAILURE; LONG TERM CARE; MEDICAL RESEARCH; MEMBRANE PERMEABILITY; MESOTHELIUM; MOLECULAR MECHANICS; MORBIDITY; MORPHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NEUROTOXICITY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; RISK FACTOR; SOLUTE; TREATMENT FAILURE; ULTRAFILTRATION; UREMIA;

ENDOTHELIAL GROWTH FACTORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GROWTH SUBSTANCES; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; PERITONEAL DIALYSIS; PERITONEUM; PERMEABILITY; UREMIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035568828     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Peritoneal dialysis
2. Peritoneal membrane failure: Differential diagnosis, evaluation, and treatment
3. The peritoneal membrane in chronic peritoneal dialysis
4. What really happens to people on long-term peritoneal dialysis?
5. The physiology of peritoneal solute transport and ultrafiltration
6. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients
7. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration
8. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis
9. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis
10. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
11. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature
12. Vascular endothelial growth factor (VEGF) and its receptors
13. Effects of nitroprusside on peritoneal mass transfer coefficients and microvascular physiology
14. The effect of a nitric oxide inhibitor (L-NAME) on peritoneal transport during dialysis in rats
15. Nitric oxide: A physiologic messenger molecule
16. A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies
17. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis
18. Pathophysiological roles of nitric oxide in inflammation
19. Role of vascular endothelial growth factor in the regulation of angiogenesis
20. Biological roles of fibroblast growth factor-2
21. Growth factors VEGF and TGF-beta1 in peritoneal dialysis
22. Spontaneous VEGF production by cultured peritoneal mesothelial cells from patients on peritoneal dialysis
23. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis
24. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability
25. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
26. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide
27. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications
28. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism
29. Advanced glycation end products: A nephrologist's perspective
30. A comparison of peritoneal transport in patients with psoriasis and uremia
31. Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients
32. Subtotal nephrectomy: A mosaic of growth factors
33. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum
34. Does removal of glucose lower the carbonyl stress of glucose containing peritoneal dialysis? Effect of dwell time on icodextrin and amino acid PD fluids
35. Inhibition of nitric oxide synthase as a potential therapeutic target
36. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
37. Clinical applications of angiogenic growth factors and their inhibitors